The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Knocking down disease: a progress report on siRNA therapeutics
Open accessAbstract
Small interfering RNAs (siRNAs), which downregulate gene expression guided by sequence complementarity, can be used therapeutically to block the synthesis of disease-causing proteins. The main obstacle to siRNA drugs — their delivery into the target cell cytosol — has been overcome to allow suppression of liver gene expression. Here, we review the results of recent clinical trials of siRNA therapeutics, which show efficient and durable gene knockdown in the liver, with signs of promising clinical outcomes and little toxicity. We also discuss the barriers to more widespread applications that target tissues besides the liver and the most promising avenues to overcome them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Rational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
RNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
Self-citationAnalysis of gene function in somatic mammalian cells using small interfering RNAs
Elbashir, S. (2002) · Methods · doi:10.1016/s1046-2023(02)00023-3 · Cited by 1,095
Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion
Thurston, T. L. M., Wandel, M. P., von Muhlinen, N., Foeglein, Á., & Randow, F. (2012) · Nature · doi:10.1038/nature10744 · Cited by 1,034
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Self-citationCell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
American Association for the Study of Liver Diseases
Popper, H. (1960) · Gastroenterology · doi:10.1016/s0016-5085(60)80094-7 · Cited by 903
siRNA function in RNAi: A chemical modification analysis
CHIU, Y.-L., & RANA, T. M. (2003) · RNA · doi:10.1261/rna.5103703 · Cited by 860
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T., & Lieberman, J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3298 · Cited by 693
Self-citationSystemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 570
Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 493
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387
Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380
Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold.
Boussif, O., Zanta, M. A., & Behr, J. (1996) · PubMed · Cited by 342
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hossbach, M., John, M., Hamilton, H. L., Chu, Q., Hegge, J. O., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 293
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†
Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290
Peer, D., Zhu, P., Carman, C. V., Lieberman, J., & Shimaoka, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608491104 · Cited by 275
Self-citationTargeting Polo-like Kinase in Cancer Therapy
Degenhardt, Y., & Lampkin, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1380 · Cited by 262
Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0376 · Cited by 260
Dysregulation of microRNA biogenesis and gene silencing in cancer
Hata, A., & Lieberman, J. (2015) · Science Signaling · doi:10.1126/scisignal.2005825 · Cited by 240
Self-citationWheeler, L. A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z., Seung, E., Deruaz, M., Dudek, T., Einarsson, J. I., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45876 · Cited by 227
Self-citationMatsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221
Cuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S. J., Gesch, J., Davis, D., van Brabant Smith, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1362 · Cited by 213
Antisense oligonucleotides: modifications and clinical trials
Sharma, V. K., Sharma, R. K., & Singh, S. K. (2014) · Med. Chem. Commun. · doi:10.1039/c4md00184b · Cited by 204
Meade, B. R., Gogoi, K., Hamil, A. S., Palm-Apergi, C., Berg, A. V. D., Hagopian, J. C., Springer, A. D., Eguchi, A., Kacsinta, A. D., Dowdy, C. F., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3078 · Cited by 191
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and Metastasis
Yao, Y.-D., Sun, T.-M., Huang, S.-Y., Dou, S., Lin, L., Chen, J.-N., Ruan, J.-B., Mao, C.-Q., Yu, F.-Y., Zeng, M.-S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003601 · Cited by 188
Self-citationRajeev, K. G., Nair, J. K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 185
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Daige, C. L., Wiggins, J. F., Priddy, L., Nelligan-Davis, T., Zhao, J., & Brown, D. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0209 · Cited by 168
Endosomolysis by Masking of a Membrane-Active Agent (EMMA) for Cytoplasmic Release of Macromolecules
Rozema, D. B., Ekena, K., Lewis, D. L., Loomis, A. G., & Wolff, J. A. (2003) · Bioconjugate Chemistry · doi:10.1021/bc0255945 · Cited by 161
Synthesis of Cluster Galactosides with High Affinity for the Hepatic Asialoglycoprotein Receptor
Biessen, E. A. L., Beuting, D. M., Roelen, H. C. P. F., van der MAREL, G. A., BOOM, J. H. V., & van Berkel, T. J. C. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00009a014 · Cited by 151
The mTOR Pathway in Hepatic Malignancies
Bhat, M., Sonenberg, N., & Gores, G. J. (2013) · Hepatology · doi:10.1002/hep.26323 · Cited by 144
Roberts, T. L., Sweet, M. J., Hume, D. A., & Stacey, K. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.605 · Cited by 131
Shi, B., Keough, E., Matter, A., Leander, K., Young, S., Carlini, E., Sachs, A. B., Tao, W., Abrams, M., Howell, B., et al. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410885 · Cited by 125
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Berezhnoy, A., Castro, I., Levay, A. K., Malek, T. R., & Gilboa, E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69856 · Cited by 123
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
Wong, S. C., Klein, J. J., Hamilton, H., Chu, Q., Frey, C. L., Trubetskoy, V. S., Hegge, J., Wakefield, D. H., Rozema, D. B., & Lewis, D. L. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0389 · Cited by 101
Gilboa-Geffen, A., Hamar, P., Le, M. T. N., Wheeler, L. A., Trifonova, R. T., Petrocca, F., Wittrup, A., & Lieberman, J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0201-t · Cited by 91
Self-citationWu, Y., Navarro, F., Lal, A., Basar, E., Pandey, R. K., Manoharan, M., Feng, Y., Lee, S. J., Lieberman, J., & Palliser, D. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2008.12.003 · Cited by 91
Self-citationByrne, M., Tzekov, R. T., Wang, Y., Rodgers, A., Cardia, J. P., Ford, G., Holton, K., Pandarinathan, L., Lapierre, J., Stanney, W., et al. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0148 · Cited by 78
Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles
Nakayama, T., Butler, J. S., Sehgal, A., Severgnini, M., Racie, T., Sharman, J., Ding, F., Shulga‐Morskaya, S., Brodsky, J., Tchangov, L., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.33 · Cited by 76
Efficient and specific gene knockdown by small interfering RNAs produced in bacteria
Huang, L., Jin, J., Deighan, P., Kiner, E., McReynolds, L. A., & Lieberman, J. (2013) · Nature Biotechnology · doi:10.1038/nbt.2537 · Cited by 70
Self-citationToxicity profiling of several common RNAi-based nanomedicines: a comparative study
Landesman‐Milo, D., & Peer, D. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0158-7 · Cited by 68
Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo
Dudek, H., Wong, D. H., Arvan, R., Shah, A., Wortham, K. A., Ying, B., Diwanji, R., Zhou, W. L., Holmes, B. R., Yang, H., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.233 · Cited by 57
Protease-triggered siRNA delivery vehicles
Rozema, D. B., Blokhin, A. V., Wakefield, D. H., Benson, J. D., Carlson, J. C., Klein, J. J., Almeida, L., Nicholas, A. L., Hamilton, H., Chu, Q., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.012 · Cited by 40
Zimmermann, T. S., Karsten, V., Harrop, J., et al. (2013) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.06.214 · Cited by 16
Sørensen, B., Mant, T., Akinc, A., Simon, A. R., Melton, L., Lynam, C., Strahs, A. L., Sehgal, A., Hutabarat, R. M., Chaturvedi, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.693.693 · Cited by 15
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
In vitro and ex vivo strategies for intracellular delivery
Stewart, M. P., Sharei, A., Ding, X., Sahay, G., Langer, R., & Jensen, K. F. (2016) · Nature · doi:10.1038/nature19764 · Cited by 885
Metadata
- Authors
- Wittrup, A., & Lieberman, J.
- Venue
- Nature Reviews Genetics
- Published
- 2015-08-18
- Volume
- 16
- Issue
- 9
- Pages
- 543-552
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2120820989
- Cited by
- 804
- References
- 88
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.